Recent Updates
Recently added Catalysts
TTRX Positive Sentiment

Watch Full Measure Cover Story Featuring Our Founder

Key Takeaway: Turn Therapeutics' founder, Bradley Burnam, was featured in a cover story on the program Full Measure, hosted by Sharyl Attkisson. The segment details the company's journey from humble beginnings to its presence on the Nasdaq. It emphasizes the mission to aid millions through innovative technology, stemming from a personal story. The coverage also includes a podcast episode, further extending its reach.
Price reaction · baseline $6.56 (2025-10-13T18:44:00.000Z) · hit during market hours · 2 other TTRX headline(s) in the window, move may be shared
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • The company received significant national media attention.
  • The segment highlights the company's journey and mission.
  • The founder's personal story adds a compelling narrative.
  • The program reaches a wide audience of 43 million households.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~32 mo
Minimal dilution risk
Lead asset
GX-03
Phase 2 · Covid19

Full Press Release Details

Friends & Shareholders,
In July, I was invited to Washington, D.C. to record an interview with Emmy Award-winning journalist Sharyl Attkisson for her nationally syndicated program, Full Measure . We had no idea when it would air, let alone considered that it would become a cover story for such a major program.
Full Measure reaches 43 million households in 79 markets across America.
The segment shares our journey from the garage floor to the Nasdaq floor. It also talks about Turn Therapeutics’ mission to help millions with a technology that began for one patient: me. Even more surprising, Sharyl followed it up with a feature episode on her podcast, expanding the reach even further.
You can watch and listen here:
🎥 Watch the Full Measure segment »
🎧 Listen to the After Hours podcast »
Receiving this level of national attention is a powerful moment for our company, our mission, and everyone who has believed in Turn from the beginning.
Bradley Burnam
Founder & CEO, Turn Therapeutics

Frequently Asked Questions

What is the Full Measure segment about?

The segment covers Turn Therapeutics' journey and mission, highlighting its founder's personal story.

Who interviewed the founder of Turn Therapeutics?

The founder was interviewed by Emmy Award-winning journalist Sharyl Attkisson.

How many households does Full Measure reach?

Full Measure reaches 43 million households across 79 markets in America.

What additional content was created from the segment?

A feature episode was also produced for Sharyl Attkisson's podcast.

Last updated: Oct 13, 2025